Minimising the risk of diabetes in patients with schizophrenia and bipolar disorder

International Journal of Psychiatry in Clinical Practice

Volumn 10, Issue 2, 2006, Pages 105-116

  Chue, Pierre ^a,c   Cheung, Raphael ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b WESTERN UNIVERSITY   (Canada)

^c NONE   (Canada)

Author keywords

Antipsychotic; Atypical; Bipolar; Diabetes; Schizophrenia

Indexed keywords

AMANTADINE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HALOPERIDOL; LITHIUM; METFORMIN; NEUROLEPTIC AGENT; NIZATIDINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; TOPIRAMATE; VALPROIC ACID; ZIPRASIDONE;

ARTICLE; BIPOLAR DISORDER; BLOOD PRESSURE MONITORING; BODY MASS; CLINICAL TRIAL; DIABETES MELLITUS; DNA POLYMORPHISM; DROWSINESS; EXERCISE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LETHARGY; LIPID BLOOD LEVEL; METABOLIC DISORDER; NUTRITION; ORAL GLUCOSE TOLERANCE TEST; PATIENT MONITORING; PHYSICAL ACTIVITY; POLYDIPSIA; POLYURIA; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SCHIZOPHRENIA; SIDE EFFECT; WAIST CIRCUMFERENCE; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 33745066913     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.1080/13651500600579084     Document Type: Article

References (91)

1. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998;21(4):518-24.
2. Regenold WT, Thapar RK, Marano C, Gavirneni S, Kondapavuluru PV. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord 2002;70(1):19-26.
3. Harris MI. Impaired glucose tolerance in the U.S. population. Diabetes Care 1989;12(7):464-74.
4. Mukherjee S, Schnur DB, Reddy R. Family history of type 2 diabetes in schizophrenic patients. Lancet 1989;1(8636):495.
5. Cassidy F, Ahearn E, Carroll BJ. Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am J Psychiatry 1999;156(9):1417-20.
6. Kohen D. Diabetes mellitus and schizophrenia: historical perspective. Br J Psychiatry 2004;47(Suppl):S64-6.
7. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002;159(4):561-6.
8. Ryan MC, Collins P, Thakore JH. Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci 2002;71(3):239-57.
9. Lean ME, Pajonk FG. Patients on atypical antipsychotic drugs: Another high-risk group for type 2 diabetes. Diabetes Care 2003;26(5):1597-605.
10. Goldman M, DeQuardo JR, Tandon R, Taylor SF, Jibson M. Symptom correlates of global measures of severity in schizophrenia. Compr Psychiatry 1999;40(6):458-61.
11. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003;160(2):284-9.
12. Kato MM, Goodnick PJ. Antipsychotic medication: effects on regulation of glucose and lipids. Expert Opin Pharmacother 2001;2(10):1571-82.
13. Gianfrancesco F, White R, Wang RH, Nasrallah HA. Antipsychotic-induced type 2 diabetes: evidence from a large health plan database. J Clin Psychopharmacol 2003;23(4):328-35.
14. Gianfrancesco F, Grogg A, Mahmoud R, Wang RH, Meletiche D. Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders. Clin Ther 2003;25(4):1150-71.
15. Lean ME, Pajonk FG. Patients on atypical antipsychotic drugs: another high-risk group for type 2 diabetes: response to Hardy and Breier. Diabetes Care 2003;26(11):3202-3.
16. Citrome LL, Jaffe AB. Relationship of atypical antipsychotics with development of diabetes mellitus. Ann Pharmacother 2003;37(12):1849-57.
17. Koro CE, Fedder DO, L'Italien GJ, Weiss S, Magder LS, Kreyenbuhl J, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. Br Med J 2002;325(7358):243.
18. Gianfrancesco FD, Grogg A, Mahmoud R, Wang RH, Nasrallah HA. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry 2002;63(10):920-30.
19. Melkersson K, Dahl ML. Adverse metabolic effects associated with atypical antipsychotics: Literature review and clinical implications. Drugs 2004;64(7):701-23.
20. WHO: Diabetes: the cost of diabetes (2004). Available at: http://www.who.int/mediacentre/factsheets/fs236/en/
21. American Diabetes Association. Consensus development conference on antipsychotic drugs and obesity and diabetes. Obes Res 2004;12:362-8.
22. American Diabetes Association. Diabetes and cardiovascular disease review (2004). Available at: http://www.diabetes.org/uedocuments/ADACardioReview4.pdf
23. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. Am J Psychiatry, Psychiatric Association 1997;154(Suppl 4):1-63.
24. National Institute of Clinical Excellence. Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. London, 2002. Available at: http//www.nice.org. Accessed 6 January, Institute for Clinical Excellence, 2002.
25. American Psychiatric Association. Practice guidelines for the treatment of patients with bipolar disorder (revision). Am J Psychiatry, Psychiatr Assoc 2002;159(4):1-50.
26. Lambert T, Chapman L, on behalf of the Australian Consensus Panel. Diabetes, Psychotic disorders and antipsychotic therapy. A Consensus Statement. www.psychiatry.unimelb.edu.au/open/diabetes_consensus
27. Newcomer JW, Nasrallah HA, Loebel AD. The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists. J Clin Psychopharmacol 2004;24(5 Suppl 1):S1-6.
28. International Diabetes Federation (2004). Available at: http://www.idf.org/home/index.cfm?node=12. Accessed January 2004.
29. Shaten BJ, Smith GD, Kuller LM, Neaton JD. Risk factors for the development of type II diabetes among men enrolled in the usual care group of the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16(10):1331-9.
30. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes 2003;27:1-152.
31. Chue P. The assessment and management of antipsychotic-associated metabolic disturbances from a psychiatric perspective. Can J Psychiatry 2004;49(3):200-7.
32. Chue P, Kovacs CS. Safety and tolerability of atypical antipsychotics in patients with bipolar disorder: prevalence, monitoring and management. Bipolar Disord 2003;5(Suppl 2):62-79.
33. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004;161(8):1334-49.
34. Melkersson KI, Dahl ML, Hulting AL. Guidelines for prevention and treatment of adverse effects of antipsychotic drugs on glucose-insulin homeostasis and lipid metabolism. Psychopharmacology (Berlin) 2004;175(1):1-6.
35. Meltzer HY. Putting metabolic side effects into perspective: risks versus benefits of atypical antipsychotics. J Clin Psychiatry 2001;62(Suppl 27):35-9; Discussion 40-1.
36. Baptista T, Kin NM, Beaulieu S, de Baptista EA. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 2002;35(6):205-19.
37. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry 1999;156(11):1686-96.
38. Aguglia E, De Vanna M, Onor ML, Ferrara D. Insight in persons with schizophrenia: Effects of switching from conventional neuroleptics to atypical antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 2002;26(7-8):1229-33.
39. Gold JM, Harvey PD. Cognitive deficits in schizophrenia. Psychiatr Clin North Am 1993;16(2):295-312.
40. Quraishi S, Frangou S. Neuropsychology of bipolar disorder: a review. J Affect Disord 2002;72(3):209-26.
41. Cavazzoni P, Hornbuckle K, Wu J, Breier A, Kotsanos J, Holman R. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United Kingdom. Int J Neuropsychopharmacology 2002;5(1):S18.
42. Wang PS, Glynn RJ, Ganz DA, Schneeweiss S, Levin R, Avorn J. Clozapine use and risk of diabetes mellitus. J Clin Psychopharmacol 2002;22(3):236-43.
43. Lambert B, Chou CH, Chang KY, Iwamoto T, Tafesse E. Assessing the risk of antipsychotic-induced type II diabetes among schizophrenics: A matched case-control study. Eur Neuropsychopharmacology 2002;12(3):S307.
44. Lee D, Fowler RB, Kadlubek PJ, Haberman M. No significant difference in the risk of diabetes mellitus during treatment with typical versus atypical antipsychotics: Results from a large observational study. Drug Benefit Trends 2002;14:46-52.
45. Buse JB, Carazzoni P, Hombuckle K, Hutchins D, Breier A, Jovanovic L. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epidemiol 2003;56(2):164-70.
46. Cunningham F, Lambert B, Miller DR, Galuck G, Kin JB, Hur K. Antipsychotic induced diabetes in veteran schizophrenia patients. Pharmacoepidemiol Drug Saf 2003;12(1):S154-5.
47. Fuller MA, Shermock KM, Secic M, Grogg AL. Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine. Pharmacotherapy 2003;23(8):1037-43.
48. Citrome L, Jaffe A, Levine J, Allingham B, Robinson J. Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatr Serv 2004;55(9):1006-13.
49. Feldman PD, Hay LK, Deberdt W, Kennedy JS, Hutchins DS, Hay DP, Hardy TA, Hoffman VP, Hornbuckle K, Breier A. Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States. J Am Med Dir Assoc 2004;5:38-46.
50. Leslie DL, Rosenheck RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry 2004;161:1709-11.
51. Ollendorf DA, Joyce AT, Rucker M. Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia. MedGen Med 2004;6(1):5.
52. Caro JJ, Ward A, Levington C, Robinson K. The risk of diabetes during olanzapine use compared with risperidone use: A retrospective database analysis. J Clin Psychiatry 2002;63(12):1135-9.
53. Sumiyoshi T, Roy A, Anil AE, Jayathilake K, Ertugrul A, Meltzer HY. A comparison of incidence of diabetes mellitus between atypical antipsychotic drugs: A survey for clozapine, risperidone, olanzapine and quetiapine. J Clin Psychopharmacol 2004;24(3):345-8.
54. Moisan J, Gregoire JP, Gaudet M, Cooper D. Exploring the risk of diabetes mellitus and dyslipidemia among ambulatory users of atypical antipsychotics: A population-based comparison of risperidone and olanzapine. Pharmacoepidemiol Drug Saf 2005;14:427-36.
55. Miller EA, Leslie DL, Rosenheck RA. Incidence of new-onset diabetes mellitus among patients receiving atypical neuroleptics in the treatment of mental illness. J Nerv Ment Dis 2005;193:387-95.
56. Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003;61(2-3):123-36.
57. Pigott TA, Carson WH, Saha AR for the Aripiprazole Study Group. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia. A placebo-controlled 26-week study. J Clin Psychiatry 2003;64:1048-56.
58. Keck PE, Marcus R, Tourkodimitris S. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003;160:1651-8.
59. Daniel DJ, Zimboff DI, Potkin SG, et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 1999;20:491-505.
60. Kingsbury SJ, Fayek M, Trufasiu D, Zada J, Simpson GM. The apparent effects of ziprasidone on plasma lipids and glucose. J Clin Psychiatry 2001;62(5):347-9.
61. Ebenbichler CF, Laimer M, Edur U, Mangweth B, Weiss E, Hofer A, et al. Olanzapine induces insulin resistance: results from a prospective study. J Clin Psychiatry 2003;64(12):1436-9.
62. Melkersson K, Hulting A-L, Brismar KE. Elevated levels of insulin, leptin and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry 2000;61:742-9.
63. Melkersson KI, Hutling AL. Insulin and leptin levels in patients with schizophrenia or related psychoses - a comparison between different antipsychotic agents. Psychopharmacology 2001;154:205-12.
64. Newcomer JW. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002;59(4):337-45.
65. Emsley R, Turner HJ, Schronen J, Botha K, Smit R, Oosthuizen PP. A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J Clin Psychiatry 2004;65:696-701.
66. Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003;160(2):290-6.
67. Melkersson KI, Dahl ML. Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses. Psychopharmacology 2003;170:157-66.
68. McQuade R, Stock E, Marcus R, Jody D, Gharbia NA, Vanveggel S, Archibald D, Carson WH. A comparison of weight gain change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 2004;65(18):47-56.
69. Simpson GM, Glick ID, Weiden PJ, Romano SJ, Siu CO. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry 2004;161(10):1837-47.
70. Simpson GM, Weiden P, Pigott T, Murray S, Siu CO, Romano S. Six-month, blinded, mulitcentre continuation study of ziprasidone versus olanzapine in schizophrenia. Am J Psychiatry 2005;162:1535-8.
71. Chue P. @Metabolic regulation and atypical antipychotic drugs. In: Csernansky G, Lauriello J, editors. Atypical antipsychotics: A bench to bedside perspective for clinicians. 1st ed. New York: Marcel Dekker Inc; 2004; p 93-128.
72. Newcomer JW. Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. J Clin Psychiatry 2004;65(18):36-46.
73. Basile VS, Masellis M, McIntyre RS, Meltzer HY, Lieberman JA, Kennedy JL. Genetic dissection of atypical antipsychotic-induced weight gain: Novel preliminary data on the pharmacogenetic puzzle. J Clin Psychiatry 2001;62:45-66.
74. Fadel J, Bubser M, Deutch AY. Differential activation of orexin neurons by antipsychotic drugs associated with weight gain. J Neurosci 2002;22:6742-6.
75. Ryan MC, Flanagan S, Kinessla U, Keeling F, Thakore JH. The effects of atypical antipstyhotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia. Life Sci 2004;74(16):1999-2008.
76. Melkesson K. Clozapine and olanzapine, but not conventional antipsychotics, increase insulin release in vitro. Eur Neuropsychopharmacol 2004;14(2):115-9.
77. Dwyer DS, Bradley RJ, Kablinger AS. Freeman AM 3rd. Glucose metabolism in relation to schizophrenia and antipsychotic drug treatment. Ann Clin Psychiatry 2001;13(2):103-13.
78. Jump DB. Fatty acid regulation of gene transcription. Crit Rev Clin Lab Sci 2004;41(1):41-78.
79. Reynolds GP, Zhang Z, Zhang X. Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain. Am J Psychiatry 2003;160:677-9.
80. Chagnon YC, Merette C, Bouchard RH, Emond C, Roy MA, Maziade M. A genome wide linkage study of obesity as secondary effect of antipsychotics in multigenerational families of eastern Quebec affected by psychoses. Mol Psychiatry 2004;9(12):1067-74.
81. Dinan TG. Stress and the genesis of diabetes mellitus in schizophrenia. Br J Psychiatry 2004;184:S72-5.
82. Sowell MO, Mukhopadhyay N, Carazzoni P, Shankar S, Steinberg HO, Breier A, et al. Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. J Clin Endocrinol Metab 2002;87(6):2918-23.
83. Sowell MO, Mukhopadhyay N, Cavazzoni P, Carlson C, Mudaliar S, Chinnapongse S. Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: A prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp. J Clin Endocrinol Metab 2003;88(12):5875-80.
84. Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: A frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 2005;62(1):19-28.
85. Nasrallah HA. Factors in antipsychotic drug selection: tolerability considerations. CNS Spectrums 2003;8(11 Suppl 2):23-5.
86. Henderson DC. Atypical antipsychotic-induced diabetes mellitus: How strong is the evidence? CNS Drugs 2002;16(2):77-89.
87. Mir S, Taylor D. Atypical antipsychotics and hyperglycaemia. Int Clin Psychopharmacol 2001;16(2):63-73.
88. Liebzeit KA, Markowitz JS, Caley CF. New onset diabetes and atypical antipsychotics. Eur Neuropsychopharmacol 2001;11(1):25-32.
89. Gough S. Diabetes and its prevention: Programmatic solutions for people with schizophrenia. Br J Psychiatry 2004;184:S106-11.
90. Nasrallah HA, Newcomer JW. Atypical antipsychotics and metabolic dysregulation: Evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol 2004;24(5 Suppl 1):S7-14.
91. Meltzer HY, Davidson M, Glassman AH, Vieweg WV. Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment. J Clin Psychiatry 2002;63(9):25-9.